Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations

Introduction : The ongoing SARS-CoV-2 pandemic is a serious threat for the health of immunocompromised patients. Among neutralizing antibody-based therapeutics, convalescent plasma containing polyclonal anti-SARS-CoV-2 immunoglobulins has promising results in both congenital and iatrogenic immunodeficiencies in oncohematological and transplant patients. Areas covered : This article discusses case reports, case series and controlled studies detailing the efficacy of convalescent plasma in immunocompromised patients. Expert opinion : Convalescent plasma, when administered at high neutralizing antibody titers, is a safe and effective treatment for frail immunocompromised patients. Genetic monitoring of refractory patients is recommended to intercept intra-host emergence of SARS-CoV-2 variants.

Automated summary

Convalescent plasma containing polyclonal anti-SARS-CoV-2 immunoglobulins has shown promising results in immunocompromised patients, especially when administered at high neutralizing antibody titers. Genetic monitoring of refractory patients is recommended to prevent the emergence of SARS-CoV-2 variants within the host.